Study authors evaluated the effect of complement C5a receptor inhibitor avacopan on renal function in ANCA-associated vasculitis.
Researchers assessed thyroid disease risk between the different forms of ANCA-associated vasculitis (AAV), and compared the clinical features of AAV in patients with and without thyroid disease.
In a safety outcome analysis, researchers assessed treatment-related damage in patients with elderly-onset ANCA-associated vasculitis.
Researchers performed a systematic review to identify cases of infection-induced antimyeloperoxidase ANCA-associated vasculitis.
Authors of this case study reported the first case of neutrophilic arterial vasculitis in COVID-19.
Avacopan is an orally-administered, small molecule designed to selectively block the complement 5a receptor on destructive inflammatory cells such as blood neutrophils.
Researchers investigated the association between specimen length and number of sections evaluated and the diagnostic yield of temporal artery biopsy for giant cell arteritis.
Authors of this report assessed the role of iloprost in the management of COVID-19-related vasculopathy.
ChemoCentryx, Inc has submitted a NDA to the FDA for acavopan in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Extended therapy with rituximab is associated with a reduced incidence of antineutrophil cytoplasmic antibody-associated vasculitis relapse in GPA or MPA.